Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

CytoMed Therapeutics Limited - Ordinary Shares (NQ:GDTC)

1.890 +0.120 (+6.77%)

Streaming Delayed Price Updated: 2:30 PM EST, Dec 8, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	296,783
Open	1.800
Bid (Size)	1.890 (4,200)
Ask (Size)	1.940 (200)
Prev. Close	1.770
Today's Range	1.800 - 2.120
52wk Range	1.650 - 4.050
Shares Outstanding	11,540,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

Today 8:00 EST

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

November 18, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

Performance

YTD	-46.0%	-46.0%
1 Month	+0.5%	+0.5%
3 Month	+3.3%	+3.3%
6 Month	-9.4%	-9.4%
1 Year	-34.6%	-34.6%

More News

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 06, 2025

Via Benzinga

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

November 06, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%

October 22, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

Why Did CytoMed Therapeutics Stock Jump 19% Today? ↗

October 14, 2025

Via Stocktwits

CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets

October 14, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition

August 28, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia

October 02, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program

August 18, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 23, 2025

Via Benzinga

Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies

July 21, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

April 28, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders

February 06, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 13, 2025

Via Benzinga

Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket ↗

January 07, 2025

Via Benzinga

Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor ↗

January 06, 2025

Via Benzinga

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial

January 06, 2025

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

November 20, 2024

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

October 07, 2024

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank

October 03, 2024

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

September 30, 2024

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

July 19, 2024

Via InvestorPlace

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

July 17, 2024

From CYTOMED THERAPEUTICS LIMITED

Via GlobeNewswire

Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration

March 20, 2024

Via Spotlight Growth

Frequently Asked Questions

Is CytoMed Therapeutics Limited - Ordinary Shares publicly traded?

Yes, CytoMed Therapeutics Limited - Ordinary Shares is publicly traded.

What exchange does CytoMed Therapeutics Limited - Ordinary Shares trade on?

CytoMed Therapeutics Limited - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares?

The ticker symbol for CytoMed Therapeutics Limited - Ordinary Shares is GDTC on the Nasdaq Stock Market

What is the current price of CytoMed Therapeutics Limited - Ordinary Shares?

The current price of CytoMed Therapeutics Limited - Ordinary Shares is 1.890

When was CytoMed Therapeutics Limited - Ordinary Shares last traded?

The last trade of CytoMed Therapeutics Limited - Ordinary Shares was at 12/08/25 02:30 PM ET

What is the market capitalization of CytoMed Therapeutics Limited - Ordinary Shares?

The market capitalization of CytoMed Therapeutics Limited - Ordinary Shares is 21.81M

How many shares of CytoMed Therapeutics Limited - Ordinary Shares are outstanding?

CytoMed Therapeutics Limited - Ordinary Shares has 22M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433